Rani Therapeutics - RANI Company profit before taxes, interest and amortization
Rani Therapeutics (RANI) is scaling B2B licensing of its robotic capsules to achieve global market capture. The current EBITDA value confirms this trend, stabilizing at 0.00. Growth is driven by alliances with industry behemoths and the replacement of injections for diabetes treatment. Meanwhile, the US-based localization of development and the humanitarian status of medicine fully shield the company's patents from geopolitical risks.
Summary analytical data breakdowns for Rani Therapeutics Holdings, Inc. (RANI)
- market value and analyst target forecast:
- issuer market value details:
- issuer book value statistics:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Rani Therapeutics|RANI - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Rani Therapeutics Holdings|RANI - Company Aggregate Debts|Debts to Book Capitalization Rani Therapeutics|RANI - Company Long-Term Debt|Company Short-Term Indebtedness Rani Therapeutics|Interim Coverage Ratio ranitherapeutics.com
- earnings and market ratios statistics:
RANI - Net Income|Expected Net Income Rani Therapeutics|RANI - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Rani Therapeutics Holdings|RANI - PEG Multiple|Business Value to Operating Income Before Depreciation Rani Therapeutics|RANI - Operating profit EBITDA|Net earnings per one share for the last twelve months Rani Therapeutics|RANI - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months ranitherapeutics.com|RANI - Earnings growth in current year|Earnings growth forecast for next year Rani Therapeutics
Summary company analytics:RANI (Rani Therapeutics)
For Rani Therapeutics, which is scaling partnerships for the oral delivery of biologics, analyzing the absolute cash result of operations allows for an assessment of the real monetization efficiency of the RaniPill platform. This indicator measures the actual volume of operating cash flow before depreciation, alerting the investor to hidden liquidity contraction and capital erosion risks even before the publication of official financial statements.
Competitors of Rani Therapeutics (RANI)
Haleon Corp (HLN) - Profit before interest, taxes and amortization|KVUE: Operating profit before deduction of amortization|veronapharma.com - Company profit before taxes, interest and amortization|MENS: Operating profit EBITDA|Ligand Pharmaceuticals Incorporated - Income before deduction of interest, taxes and amortization|AMRX (Amneal Pharmaceuticals Inc) - Operating profit EBITDA|Profit before interest, taxes and amortization Perrigo Corp PRGO|Profit before payment of interest, taxes and amortization Alvotech (ALVO)|LQDA (liquidia.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Galapagos GLPG|Income before deduction of interest, taxes and amortization ANIP|MannKind Corp. - Operating profit EBITDA|AMPH - Operating profit EBITDA|Pacira BioSciences (PCRX) - Profit before payment of interest, taxes and amortization|Operating profit before amortization SPRY|TBPH (Theravance Biopharma, Inc.) - Operating profit EBITDA|Aquestive Therapeutics Inc (AQST) - Operating income before deduction of amortization|Operating profit before deduction of amortization SCPH (scPharmaceuticals Inc.)|TECX (tectonictx.com) - Income before deduction of interest, taxes and amortization|Tonix Pharmaceuticals - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization SXTC (SXT Pharmaceuticals)|Eupraxia Pharma - Operating profit EBITDA|Income before deduction of interest, taxes and amortization BHST (BioHarvest Sciences, Inc.)|EXOZ: Operating profit EBITDA|Profit before interest, taxes and amortization Oramed Pharmaceuticals Inc. (ORMP)|Profit before payment of interest, taxes and amortization Entera Bio Ltd|HYFT: Income before deduction of interest, taxes and amortization|Operating profit EBITDA ABVC|Operating profit EBITDA Cumberland Pharmaceuticals Inc (CPIX)|Profit before payment of interest, taxes and amortization Quantum BioPharma Limited QNTM|FGEN (FibroGen Corporation) - Profit before deduction of interest, taxes, depreciation and amortization|Telomir Pharmaceuticals - Operating profit EBITDA|Profit before interest, taxes and amortization Synergy CHC Corp|RLYB (rallybio.com) - Operating profit before deduction of amortization|Lexaria Bioscience Corp. (LEXX) - Operating profit EBITDA|Operating profit before deduction of amortization PULM|PTHL (Pheton) - Company profit before taxes, interest and amortization|Operating profit EBITDA APM|Operating income before deduction of amortization lyratherapeutics.com|Operating profit EBITDA IBO (Impact BioMedical)|TNFA - Operating profit before deduction of amortization|YCBD - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization PainReform Corp PRFX|altamiratherapeutics.com (CYTO) - Profit before payment of interest, taxes and amortization|lipella.com - Income before deduction of interest, taxes and amortization|OPTN (OptiNose) - Operating profit EBITDA|Operating profit EBITDA Pieris Pharmaceuticals Inc|Profit before payment of interest, taxes and amortization Procaps Group SA (PROC)|Petros Pharma - Operating profit before amortization|Operating profit EBITDA QLI (Qilian International)|Operating income before deduction of amortization acelyrin.com (SLRN)|TFFP - Profit before payment of interest, taxes and amortization
